By a News Reporter-Staff News Editor at Medical Letter on the CDC& FDA CardioCell LLC has just received the FDA's investigational new drug approval for a United States- based, Phase IIa clinical study using its allogeneic stem-cell therapy to treat subjects with chronic heart failure, which generates more than 1 million hospitalizations annually.
By a News Reporter-Staff News Editor at Heart Disease Weekly From Alexandria, Virginia, NewsRx journalists report that a patent by the inventors Meier, Eddi; Riber, Ditte; Skovgaard, Marie; Larsen, Bjarne Due; Daugaard, Jens Rosengren, filed on December 15, 2008, was published online on April 1, 2014. The patent's assignee for patent number 86859
April 20 Two years ago, Oklahoma National Guard Capt. Matt Smothermon spent months trying to write a single page that would get him back into law school. But the therapy, commonly used to treat divers with decompression sickness, hasn't received FDA approval for the treatment of brain injury.
Pradaxa was approved by the FDA in 2010 to prevent blood clots and strokes in patients with atrial fibrillation. The Institute for Safe Medication Practices has also advised bleeding from Pradaxa could be 5 times as likely to cause death***. Now, DrugNews has learned the FDA has approved the usage of Pradaxa for DVT and pulmonary embolism, in addit
Ground Fluor Pharmaceuticals Inc. declared that a vote of confidence from the National Science Foundation helped a Lincoln- based medical technology startup company attract and close its first round of funding. Cambridge, Mass.- based Cedarville Investments Ltd. has put in in the specialty pharmaceutical company, which has developed a new way to pr
By a News Reporter-Staff News Editor at Marketing Weekly News Particle Sciences, a drug delivery Contract Development and Manufacturing Organization, announced that they have entered into an exclusive agreement with Actavis plc, a leading specialty pharmaceutical company, to develop an unnamed complex generic product. Actavis will have responsibi
April 19 Pharmacist Larry Cowan can flip through his records and spot the generic drugs that have taken big price jumps in the past year or so. "Now the price is close to 10 times that," said Cowan, owner of Glenview Professional Pharmacy in Richland Hills. While the FDA in the past month removed doxycyline from its shortage list, it still costs
Teva Pharmaceutical Industries Ltd. announced that while the Chief Justice of the United States found that Teva had demonstrated a fair prospect of success on the merits in its appeal of a decision from the United States Court of Appeals for the Federal Circuit that invalidated the claim of U.S. Teva will continue pursuing its appeal in the S
By a News Reporter-Staff News Editor at Drug Week AmpliPhi BioSciences Corporation., the global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced that Philip Young, President and CEO, will be presenting a corporate overview at the 13th Annual Needham Healthcare Conference on Tue
Produced by EBD Group in collaboration with the Massachusetts Biotechnology Council, the September 22-24 event will bring the global life science industry to Boston to facilitate strategic collaborations with leading companies. AstraZeneca, Bayer HealthCare, Bristol Myers Squibb, EMD Serono, Novo Nordisk, and Shire are just a few large drug develop
Boston Scientific Corp. has received FDA approval for its latest generation of defibrillators and heart failure devices designed to advance patient care. These newly approved devices continue the Boston Scientific history of projected longevity and a six-year CRT-D warranty. Extending the Boston Scientific portfolio of defibrillators, the ICDs in t
Cellceutix Corp., a clinical stage biopharmaceutical company developing therapies in oncology, dermatology, and antibiotic applications, reports favorable results in a recently completed preclinical study evaluating its novel antibiotic compounds against specific strains of multi-drug resistant Klebsiella pneumoniae. According to a release, in a...
WASHINGTON The Supreme Court has declined to temporarily block a lower court ruling that opens the world's best-selling multiple sclerosis drug to competition from generic rivals. Teva claims the U.S. Court of Appeals for the Federal Circuit wrongly overturned five of its patents for the drug. That ruling allows rivals Mylan Inc., Momenta Pharma
Release date- 17042014- The U.S. Food and Drug Administration today approved Ragwitek, the first allergen extract administered under the tongue to treat short ragweed pollen induced allergic rhinitis, with or without conjunctivitis, in adults 18 years through 65 years of age. 'The approval of Ragwitek offers millions of adults living with ragweed p
FDA is committed both to responding rapidly to public health threats and to approving products for serious medical conditions in a timely manner. In addition, the approval of any vaccine in the United States requires submission of a Biologics License Application to the FDA by a manufacturer so that the FDA can review the vaccine's safety and effect
By a News Reporter-Staff News Editor at Insurance Weekly News FDB, the leading provider of clinical drug knowledge that helps improve medication-related decisions and patient outcomes, announced that it will present a poster at the Academy of Managed Care Pharmacy 26th Annual Meeting, April 1- 4, 2014, in Tampa, Florida and the International Soci
Peter G. Traber, President, Chief Executive Officer, and Chief Medical Officer of Galectin Therapeutics Inc. "These positive results have propelled the enrollment of the second cohort with strong participation across our clinical trial sites. In 2013, Galectin Therapeutics received Fast Track designation from the FDA for this clinical development..
ALEXANDRIA, Va., April 18 GlaxoSmithKline, Philadelphia, has been assigned a patent developed by seven co-inventors for "tetrahydroquinoline derivatives and their pharmaceutical use." The co-inventors are Emmanuel Hubert Demont, Stevenage, United Kingdom, Neil Stuart Garton, Stevenage, United Kingdom, Romain Luc Marie Gosmini, Les Ulis, France, T
Organizing Committee Members Include: Wolfgang Sadee, The Ohio State University, USA; Diane J Burgess, University of Connecticut, USA; Lakshmi Putcha, NASA, USA; Sean Zhang, Sino-American Pharmaceutical Professionals Association, USA; Mirko Diksic, McGill University, Canada; Mohammad Khalid Parvez, King Saud University, Saudi Arabia;. OMICS Group o
PanOptica, Inc., a private biopharmaceutical company focusing on licensing and developing ophthalmology therapies, announced that it has raised up to $45 million in a Series B financing to fund the clinical program for its lead compound, PAN-90806, a pharmacologically small-molecule selective inhibitor of VEGF signaling being investigated as a topi
By a News Reporter-Staff News Editor at Health& Medicine Week From Alexandria, Virginia, NewsRx journalists report that a patent by the inventors Heacock, Craig S.; Parikh, Alpa B.; Patel, Piyush R., filed on August 21, 2012, was published online on April 1, 2014. The patent's assignee for patent number 8686047 is Cephalon, Inc.. No. 4,177,290, a
By a News Reporter-Staff News Editor at Drug Week From Alexandria, Virginia, NewsRx journalists report that a patent by the inventors Gilbert, Julian Clive; Gristwood, Robert William; Cooper, Nicola; Fox, Gabriel, filed on July 26, 2012, was published online on April 1, 2014. The patent's assignee for patent number 8686019 is Acacia Pharma Limite
By a News Reporter-Staff News Editor at Insurance Weekly News People who are at high-risk for opioid abuse use had significantly higher total medical costs than those who were not at high risk according to a new study by Prime Therapeutics. The Centers for Medicare& Medicare Services defines high risk as "using a daily morphine equivalent dose of
Pomerantz LLP has filed a class action lawsuit against The Medicines Company and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and docketed under 2:33- av-00001, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Medicines securities between F
Teva Pharmaceutical Industries announced the launch of the generic equivalent to Lunesta, 1, 2 and 3 mg, in the United States. According to a release, Lunesta Tablets, marketed by Sunovion Pharmaceuticals, had annual sales of approximately $852 million in the United States, according to IMS data as of December 2013. Teva Pharmaceutical Industries i